Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
1998-02-06
2002-05-07
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S243100, C435S220000, C514S002600, C530S350000
Reexamination Certificate
active
06383483
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to new staphylokinase derivatives with reduced immunogenicity, their identification, production and use in the treatment of arterial thrombosis and the preparation of a pharmaceutical composition for treating arterial thrombosis. More in particular it relates to the use of engineered staphylokinase derivatives for the preparation of a pharmaceutical composition for treating myocardial infarction.
2. Description of the Related Art
Staphylokinase, a protein produced by certain strains of
Staphylococcus aureus,
which was shown to have profibrinolytic properties more than 4 decades ago (1,2) appears to constitute a potent thrombolytic agent in patients with acute myocardial infarction (3,4). The staphylokinase gene has been cloned from the bacteriophages sakøC (5) and sak42D (6) as well as from the genomic DNA (sakSTAR) of a lysogenic
Staphylococcus aureus
strain (7). The staphylokinase gene encodes a protein of 163 amino acids, with amino acid 28 corresponding to the NH
2
-terminal residue of full length mature staphylokinase (6,8,9). The mature protein sequence of the wild-type variant SakSTAR (9) is represented in FIG.
1
. Only four nucleotide differences were found in the coding regions of the sakøC, sak42D and sakSTAR genes, one of which constituted a silent mutation (6,8,9).
SUMMARY OF THE INVENTION
In a plasma milieu, staphylokinase is able to dissolve fibrin clots without associated fibrinogen degradation (10-12). This fibrin-specificity of staphylokinase is the result of reduced inhibition by &agr;
2
-antiplasmin of plasmin.staphylokinase complex bound to fibrin, recycling of staphylokinase from the plasmin.staphylokinase complex following inhibition by &agr;
2
-antiplasin, and prevention of the conversion of circulating plasminogen.staphylokinase to plasmin.staphylokinase by &agr;
2
-antiplasmin (13-15). In addition staphylokinase has a weak affinity for circulating but a high affinity for fibrin-bound plasminogen (16) and staphylokinase requires NH
2
-terminal processing by plasmin to display its plasminogen activating potential (17). In several experimental animal models, staphylokinase appears to be equipotent to streptokinase for the dissolution of whole blood or plasma clots, but significantly more potent for the dissolution of platelet-rich or retracted thrombi (18,19).
Staphylokinase is a heterologous protein and is immunogenic in man. The intrinsic immunogenicity of staphylokinase, like that of streptokinase, clearly hampers its unrestricted use. Not only will patients with preexisting high antibody titers be refractory to the thrombolytic effect of these agents, but allergic side effects and occasional life-threatening anaphylaxis may occur (20). Because both streptokinase and staphylokinase are heterologous proteins, it is not obvious that their inmmunogenicity could be reduced by protein engineering. Indeed, no successful attempts to generate active low molecular weight fragments from streptokinase have been reported. In staphylokinase, deletion of the NH
2
-terminal 17 amino acids or the COOH-terminal 2 amino acids inactivates the molecule, which in addition is very sensitive to inactivation by site-specific mutagenesis (21).
Nevertheless, we have, surprisingly, found that the wild-type staphylokinase variant SakSTAR (9) contains three non-overlapping immunodominant epitopes, at least two of which can be eliminated by specific site-directed mutagenesis, without inactivation of the molecule (22). These engineered staphylokinase variants are less reactive with antibodies elicited in patients treated with wild-type staphylokinase, and are significantly less immunogenic than wild-type staphylokinase, as demonstrated in rabbit and baboon models and in patients with peripheral arterial occlusion (22).
The present invention relates to general methods for the identification, production and use of staphylokinase derivatives showing a reduced antigenicity and immunogenicity as compared to wild-type staphylokinase. The derivatives have essentially the amino acid sequence of wild-type staphylokinase or modified versions thereof and essentially intact biological activities, but have a reduced reactivity with a panel of murine monoclonal antibodies and/or with antibodies induced in patients by treatment with wild-type SakSTAR.
The invention also relates to a method for producing the derivatives of the invention by preparing a DNA fragment comprising at least the part of the coding sequence of staphylokinase that provides for its biological activity; performing in vitro site-directed mutagenesis on the DNA fragment to replace one or more codons for wild-type amino acids by a codon for another amino acid; cloning the mutated DNA fragment in a suitable vector; transforming or transfecting a suitable host cell with the vector; culturing the host cell under conditions suitable for expressing the DNA fragment and purifying the expressed staphylokinase derivative to homogeneity; preferably the DNA fragment is a 453 bp EcoRI-HindIII fragment of the plasmid pMEX602sakB (22,23), the in vitro site-directed mutagenesis is preferably performed by spliced overlap extension polymerase chain reaction with Vent DNA polymerase (New England Biolabs) or Taq polymerase (Boehringer Mannheim) and with available or generated wildtype sakSTAR or sakSTAR variants as template (24).
The invention also relates to pharmaceutical compositions comprising at least one of the staphylokinase derivatives according to the invention together with a suitable excipient, for treatment of arterial thrombosis. Pharmaceutical compositions, containing less immunogenic staphylokinase variants as the active ingredient, for treating arterial thrombosis in human or veterinary practice may take the form of powders or solutions and may be used for intravenous, intraarterial or parenteral administration. Such compositions may be prepared by combining (e.g. mixing, dissolving etc.) the active compound with pharmaceutically acceptable excipients of neutral character (such as aqueous or non-aqueous solvents, stabilizers, emulsifiers, detergents, additives), and further, if necessary with dyes.
Furthermore the invention relates to the use of the staphylokinase derivatives for the treatment of arterial thrombosis, in particular myocardial infarction, and to the use of staphylokinase derivatives for the preparation of a pharmaceutical composition for the treatment of arterial thrombosis, in particular myocardial infarction.
REFERENCES:
patent: 4532211 (1985-07-01), Sako et al.
patent: 5336495 (1994-08-01), Collen et al.
patent: 5475089 (1995-12-01), Matsuo et al.
patent: 5695754 (1997-12-01), Collen
patent: 0721982 (1996-07-01), None
Silewce et al. (1995) J. Biol. Chem. 270 : 27192-27198.*
Regenmortel (1986) TIBS 11 : 36-39.*
Bowie et al. (1990) Science 247 : 1307-1310.*
Collen, D. et al; Thrombolytic properties of poorly immunogenic variants of recombinant staphylokinase; p. 30 (Jun. 1998).
Collen, D. et al; “Recombinant staphylokinase variants with altered immunoreactivity III: Species variability of antibody binding patterns” pp. 455-463 (Jan. 1997).
Collen, D. et al: “Recombinant staphylokinase variants with altered immunoreactivity I: Construction and characterization” p. 197-206 (Jul. 15, 1996).
Collen, D. et al: “Recombinant staphylokinase variants with altered immunoreactivity IV: Identification of variats with reduced antibody induction but intact potency” pp. 463-472 (Jan. 21, 1997).
Collen et al. “Primary structure and gene structure of staphylokinase.” Fibrinolysis 6: 226-231 (1992).
Collen et al. “Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase.” Fibrinolysis 6: 232-242 (1992).
Collen “Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction.” Circulation 87: 1850-1853 (1993).
Collen et al. “Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.” Circulatio
Pak Michael
Webb Ziesenheim & Logsdon Orkin & Hanson, P.C.
LandOfFree
Staphylokinase derivatives with cysteine substitutions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Staphylokinase derivatives with cysteine substitutions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staphylokinase derivatives with cysteine substitutions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2838271